BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Oligonucleotide therapeutics - the emerging medicine class - a re harnessing the therapeutic benefit of targeting genetic material via a ntisense\, mRNA\, RNAi\, saRNA and siRNA. Their market growth: CAGR of 13 .7% projected to reach USD 8.2 billion by 2024 is driven by their potenti al to provide more efficacious and less toxic alternatives to small molec ules. They bring about the ability to affect targets that have been consi dered "non-draggable". Heavy investments in oligonucleotide therapeutic d iscovery have created an emerging market need for drug delivery technolog ies.\n\nSMi's inaugural Oligonucleotide Therapeutics and Delivery confere nce is here to keep you updated. By bringing together leading representat ives of pharmaceutical\, biotechnology and academic institutions\, the 2- day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the bi ggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems\, the conference will address delivery to non-h epatocyte cells such as cancerous tissues and overview the most successfu l platforms. Discussions will be centered around improving targeted thera py uniting the field's biggest players to share their opinions.\n\nEstabl ished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the co nversation around maximizing the potential of oligo-based treatments.\n\n Benefits of attending:\n\n- Gain first-hand insight into oligonucleotide therapy clinical success of the latest developments for novel agents- Lis ten to case studies presenting the latest candidates undergoing pre-clini cal and clinical research- Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery- Explore the chemistry of oligonucleotide therapeutics and examine novel applications of antisense oligonucleotides in the AstraZeneca Deep Dive- Engage in th e latest innovations of oligonucleotide therapeutics with insights into i mmunochemotherapeutics\, ocular indications and Duchenne Muscular Dystrop hy\n\nPlus\, an interactive half day pre-conference workshop on Target Di scovery for RNA TherapeuticsWorkshop Leader: Martin Akerman\, Chief Techn ology Officer\, Envisagenics\n\nCHAIR FOR 2021:Nagy Habib\, Professor of Surgery\, Imperial College\, Co-founder MiNA therapeutics\, Imperial Coll ege London\n\nFEATURED 2021 SPEAKERS INCLUDE:\n\n- David Evans\, Chief Sc ientific Officer\, Sirnaomics\, Inc- Stefan Vonhoff\, VP Chemistry and Ma nufacturing\, NOXXON Pharma AG- Adrien Weingartner\, Principal Scientist\ , Group Leader Drug Delivery\, Silence Therapeutics AG- Tom Baladi\, Post doctoral Research Fellow\, AstraZeneca- Maria Luisa Pineda\, CEO and Co-f ounder\, Envisagenics- Ekkehard Leberer\, Senior Director\, R and D Allia nce Management\, Sanofi- Michelle Lynn Hall\, Senior Director\, Novel The rapeutic Modalities\, Eli Lilly and Company- Jimmy Weterings\, Principal Scientist\, AstraZeneca- Arthur A Levin\, Chief Scientific Officer\, Avid ity Biosciences Inc- Meiling LI\, Senior Scientist\, F. Hoffmann-La Roche Ltd\n\nWho should attend:Executives\, Directors\, VPs\, Heads\, Principa ls\, Managers of:- RNA Biology/Discovery- Novel Therapeutic Modalities- I nnovation Technologies- C-level Scientific Executives- Formulation and Dr ug Delivery- Clinical Research and Development- Cell Biology\n\nEARLY-BIR D RATES:- BOOK BY 28TH MAY AND SAVE £200 \;- BOOK BY 30TH JUNEAND SAV E £100 \;\n\nAdditional Contact Info:T: +44 (0)20 7827 6088E: hsidhu@ smi-online.co.uk\n\nLinkedIn: @SMi PharmaTwitter: #SMiOligonucleotides\n DTEND:20210923T173000 DTSTAMP:20260512T223116Z DTSTART:20210922T090000 LOCATION:Holiday Inn London - Kensington Forum\, 97\, Cromwell Road\, Lond on\, Greater London\, SW7 4DN\, SEQUENCE:0 SUMMARY:Oligonucleotide therapeutics - the emerging medicine class - are h arnessing the therapeutic benefit of targeting genetic material via antis ense\, mR... UID:4192ba2a-a60c-427c-bd8a-d951c51f30ab END:VEVENT END:VCALENDAR